WO1999012966A1 - Peptides comportant une sequence immunodominante derivant de la glycoproteine de l'oligodendrocyte myelinique humain - Google Patents

Peptides comportant une sequence immunodominante derivant de la glycoproteine de l'oligodendrocyte myelinique humain Download PDF

Info

Publication number
WO1999012966A1
WO1999012966A1 PCT/SE1998/001618 SE9801618W WO9912966A1 WO 1999012966 A1 WO1999012966 A1 WO 1999012966A1 SE 9801618 W SE9801618 W SE 9801618W WO 9912966 A1 WO9912966 A1 WO 9912966A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
nucleic acid
acid molecule
therapy
peptides
Prior art date
Application number
PCT/SE1998/001618
Other languages
English (en)
Inventor
Magnus Andersson
Christopher Linington
Tomas Olsson
Erik WALLSTRÖM
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Priority to EP98944386A priority Critical patent/EP1012183A1/fr
Priority to AU91938/98A priority patent/AU9193898A/en
Priority to CA002301684A priority patent/CA2301684A1/fr
Publication of WO1999012966A1 publication Critical patent/WO1999012966A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • a peptide comprising an immunodominant sequence derived from human myelin oligodendrocyte glycoprotein ( MOG), nucleic acid molecules capable of encoding the peptide and the use of such peptide or nucleic acid in medical therapy or screening.
  • MOG myelin oligodendrocyte glycoprotein
  • MS multiple sclerosis
  • CNS central nervous system
  • MOG myelin oligodendrocyte glycoprotein
  • Identification of the protein fragments of MOG which are targets for autoreactive immune cells i.e. the immunodominant epitopes may allow these fragments to be used therapeutically.
  • WO 95/07096 purports to describe methods for the therapy of MS by administration of MOG protein and MOG derived peptides, however it concludes that the important immunological and encephalitogenic determinants of the MOG molecule lie between peptide 35-55.
  • WO 95/06727 describes the complete sequence of human MOG and proposes its use in the therapy of autoimmune conditions. It also describes a number of MOG fragments which it suggests on the basis of an algorithm may be useful in moderating the autoimmune response. However no indication is given as to whether the predicted peptides do possess significant activity in this regard . No disclosure or suggestion of the peptides of the present invention is made.
  • the demyelination of the CNS which occurs in MS is mediated by T cells which are responding to particular antigens (autoantigens) present in the myelin sheath.
  • This process involves the uptake and subsequent proteolytic cleavage of the relevant antigen by antigen presenting cells which present the antigen to the T cells in association with a Class II major histocompatibility complex protein . If the T cell epitope of the relevant autoantigen can be identified it can be used to induce non-responsiveness to that autoantigen. This may be done by a variety of known tolerogenic protocols e.g. mucosal tolerance. This offers a therapeutic approach to autoimmune conditions such as MS which depends on the ability to identify the particular immunodominant epitope within the autoantigen which is responsible for eliciting the autoimmune reaction.
  • peptide(63-87) contains an immunodominant peptide sequence which significantly increases its ability to act as a target for autoimmune cells isolated from patients suffering from MS.
  • the present invention therefore provides purified peptide (63-87), or immuno-dominant fragments thereof.
  • the sequence of peptide(63-87) is:
  • PEYRGRTELLKDAIGEGKVTLRIRN a combination comprising a peptide (63-87) of the present invention and one or more sub-dominant MOG peptides.
  • the sub dominant peptide is selected from peptides:-
  • nucleic acid molecules preferably DNA molecules capable of encoding a peptide of the present invention and nucleic acid vectors comprising such nucleic acid molecules and cells and cell lines comprising such nucleic acid molecules or vectors .
  • nucleic acid molecules, vectors or cells may be used either in the synthesis of a peptide of the present invention, for subsequent administration to a patient or they may be used directly in therapy.
  • a naked DNA molecule of the present invention may be administered directly to a patient as part of a therapy known as DNA vaccination ( Waisman, A. Nature Medicine, Vol. 2 , 899-905[1996]).
  • Nucleic acid molecules of the present invention include all redundant sequences thereof i.e. all nucleic acid sequences capable of encoding a peptide of the present invention.
  • the most preferred nucleic acid sequence according to the present invention is that encoding peptide(63-87) which is most preferably:
  • a pharmaceutical composition comprising a peptide of the present invention and optionally one or more sub-dominant MOG peptides, for use in medical therapy, particularly therapy of multiple sclerosis, is also provided.
  • a peptide' means a peptide derived from another peptide of the present invention by deletion of one or more amino acids ,or addition or substitution of one or more amino acids of the peptide with one or more natural or non- natural amino acids, or the chemical modification e.g. glycosylation of the peptide to improve its efficacy and/or pharmacokinetic poperties.
  • Such processes of addition, deletion, substitution or modification should be such as not substantially to alter the tolerogenic properties of the peptide.
  • the invention also encompasses peptidomimetics of peptides of the present invention.
  • the term 'isolated peptide' refers to any peptide, irrespective of its method of synthesis, which is locationally distinct from the naturally occurring protein sequence of which it forms a part in nature.
  • 'medical therapy includes the treatment, prophylaxis and diagnosis of pathological conditions.
  • a peptide of the present invention may be used in the identification of an individual liable to develop symptoms of MS or in the diagnosis of a patient presenting sub-clinical or clinical symptoms of MS.
  • lymphocyte cells removed from an individual may be exposed in vitro to a peptide of the present invention and the ability of the peptide to stimulate an immune reaction in the isolated cells may be measured by known techniques, in particular the techniques described in Example 1 hereinafter .
  • Diagnostic kits comprising a peptide of the present invention are also comprised within the present invention.
  • the present invention also provides for methods of therapy of autoimmune conditions such as MS, comprising the administration to an individual requiring such therapy of a therapeutically effective amount of a peptide, nucleic acid, cell or cell line of the present invention.
  • Peptides of the present invention may be generated either using peptide chemical synthesis or when all amino acids of the peptide are naturally occurring amino acids, by recombinant nucleic acid technologies. Both of these technologies are well known to those skilled in the art.
  • the invention also includes processes for the synthesis of peptides , nucleic acids or cell lines of the present invention.
  • a method of making a peptide of the invention by a chemical process in which individual amino acid residues or fragments of peptides of the invention are joined to form peptide bonds and wherein protecting groups are optionally employed at the beginning and/ or end of the process.
  • a suitable effective dose of peptides of the invention generally lies in the range of from about 0.0001 ⁇ mol/kg to about lOOO ⁇ mol/kg body weight, preferably from about 0.003 to about 300 ⁇ mol/kg body weight, e.g. in the range of from about 0.001 to 100 ⁇ mol/kg body weight, for example, 0.03 to 3.0 ⁇ mol/kg body weight.
  • the total dose may be given as a single dose or multiple doses, e.g two to six times per day.
  • the dose range would be about 2.25 ⁇ mol/kg/day to 225 ⁇ mol/kg/day and a typical dose could be about 100 ⁇ mol of peptide.
  • discrete multiple doses are indicated treatment might typically be 25 ⁇ mol of a peptide of the invention given up to 4 times per day.
  • peptides of the invention may be given on alternate days or even once or twice a week or even less frequently e.g. once a month or once or twice a year. The skilled addressee will appreciate that an appropriate administrative regimen would be at the discretion of the physician or veterinary practitioner.
  • Formulations of the present invention for medical use, comprise a peptide of the invention or a salt thereof together with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients e.g. cytokines or other immunomodulating agents which may beconjugated to an active carrier delivery system such as cholera toxin B subunit (CTB) which may provide for improved mucosal uptake.
  • CTB cholera toxin B subunit
  • the carrier(s) should be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and substantially non-deleterious to the recipient thereof.
  • free acid addition salts e.g. hydro-halo salts
  • the salts will be pharmaceutically acceptable.
  • Suitable acid addition salts include those formed from hydrochloric, hydrobromic, nitric, perchloric, sulphuric, citric, tartaric, phosphoric, lactic, benzoic, glutamic, oxalic, aspartic, pyruvic, acetic, succinic, fumaric, maleic, oxaloacetic, isethionic, stearic, phthalic ⁇ methanesulphonic, p-toluene sulphonic, benzenesulphonic, lactobionic, glucuronic and trifluoracetic acids.
  • Suitable base salts include inorganic base salts such as alkali metal (e.g.
  • salts will be pharmaceutically acceptable.
  • alkaline earth metal e.g. calcium
  • organic base salts e.g. phenylethylbenzylamine, dibenzylethylenediamine, ethanolamine and diethanolamine salts
  • amino acid salts e.g. lysine and arginine.
  • the salts will be pharmaceutically acceptable.
  • the present invention therefore, further provides a pharmaceutical formulation comprising a peptide of the invention together with a pharmaceutically acceptable carrier therefor.
  • a pharmaceutical formulation comprising a peptide of the invention can include more than one peptide of the invention.
  • a pharmaceutical formulation may comprise at least two peptides of the invention or a mixture of peptides of the invention.
  • a method for the preparation of a pharmaceutical formulation comprising bringing into association a peptide, nucleic acid or cell of the present invention, and a pharmaceutically acceptable carrier therefor.
  • a peptide, nucleic acid or cell of the present invention may be administered by any route appropriate to the relevant therapeutic molecule or cell and to the condition to be treated, suitable routes including oral, intra-tracheal, rectal, nasal, topical (including buccal and sublingual), vaginal, and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal, intraperitoneal, and epidural). It will be appreciated that the route may vary with, for example, the condition of the recipient.
  • Preferred formulations are those suitable for oral, nasal or intra-tracheal administration. Most preferred formulations are those suitable for oral administration.
  • Formulations for topical administration in the mouth include lozenges comprising the peptide(s) in a flavoured basis, usually sucrose and acacia and tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouth washes comprising the peptide(s) in a suitable liquid carrier.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, lozenges comprising the peptide(s) in a flavoured base, usually sucrose and acacia and tragacanth; pastilles comprising the active ingredient(s) in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouth washes comprising the active ingredient(s) in a suitable liquid carrier.
  • Each formulation generally contains a predetermined amount of the active peptide(s); as a powder or granules; or a solution or suspension in an aqueous or non-aqueous liquid such as a syrup, an elixir, an emulsion or draught and the like.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active peptide(s) in a free-flowing form such as a powder or granules, optionally mixed with a binder, (eg povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose), surface active or dispersing agent.
  • a binder eg povidone, gelatin, hydroxypropylmethyl cellulose
  • lubricant e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose
  • disintegrant e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered peptide(s) moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile.
  • a syrup may be made by adding the active peptide(s) to a concentrated, aqueous solution of a sugar, for example, sucrose, to which may also be added any necessary ingredients.
  • a sugar for example, sucrose
  • Such accessory ingredient(s) may include flavourings, an agent to retard crystallisation of the sugar or an agent to increase the solubility of any other ingredients, such as apolyhydric alcohol, for example, glycerol or sorbitol.
  • the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives, (including antioxidants) and the like.
  • accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives, (including antioxidants) and the like.
  • Emulgents and emulsion stabilisers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl mono- stearate and sodium lauryl sulphate.
  • Formulations for rectal administration may be presented in any suitable form e.g. as a suppository with a suitable base comprising peptide(s) of the invention in admixture with a neutral fatty base, for example cocoa butter, or, for example in admixture with a salicylate, or in the form of solutions and suspensions.
  • formulations in the form of gelatin rectal capsules comprising active peptide(s) of the invention in admixture with vegetable oil(s) or paraffin oil can be used.
  • Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns. Where the particle size relates to an active substance in particle form per se, the particle size may be in the range of from 2 to 500 microns.
  • Coarse powder formulations can be administered by rapid inhalation through the nasal passage from a container of the powder held up close to the nose.
  • Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops include aqueous or oily solutions of the active ingredient.
  • peptides of the invention may be formulated in pressurised metered dose inhalers or dry powder inhalers for oral or nasal inhalation or in liquid formulations for nebulisation.
  • the active peptide(s) is micronised or otherwise processed to a particle size suitable for inhalation therapy (mass median diameter ⁇ 10 ⁇ m).
  • the micronised peptide(s) can be suspended in a liquefied propellant or a mixture of liquefied propellants. Such propellants can also, but not necessarily act as solvents. In either case, the micronised peptide(s) can be filled into a container equipped, for example with a metering valve.
  • Suitable propellants include those commonly employed in the art, such as, hydrofluoroalkanes (HFAs).
  • HFAs hydrofluoroalkanes
  • the HFA propellants can be present in any mixture which is appropriate for delivering peptide(s) of the invention to MALT.
  • suitable HFAs for use in the invention include tetrafluoroethane (eg propellant 134a (Hoechst)) and heptafluoropropane (eg propellant 227 (Hoechst)).
  • surfactants can also be present in such formulations, for example, sorbitan trioleate, lecithin, oleic acid and the like, the use of surfactants being to increase the physical stability of the peptide(s) preparation.
  • the formulation can also contain solvents, such as ethanol, to improve the solubility of the peptide(s) in the chosen propellant.
  • Active peptides of the invention may be delivered through inhaling devices suitable for dry powder inhalation, such as portable inhaler devices and the like.
  • the active peptide(s) of the invention can be used either alone or in combination with a carrier, such as lactose, mannitol, or glucose.
  • a carrier such as lactose, mannitol, or glucose.
  • the selection of carrier is not critical, provided that the physiological action of the peptide(s) of the invention is substantially unimpaired.
  • Other additives may also be included in powder formulations as required e.g. to maintain stability etc. Again, such additives should be such so as not to substantially interfere with the physiological and hence therapeutic effect of the peptide(s) of the invention.
  • the inhaling device can be of any type known in the art, such as a single dose inhaler having a predetermined dose or a multi-dose inhaler wherein the dose is measured by a metering unit within the inhaler or is delivered from an assembly of predetermined doses.
  • Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the recipient.
  • Such formulations suitably comprise a solution of a pharmaceutically and pharmacologically acceptable acid addition salt of a peptide(s) of the invention that is isotonic with the blood of the recipient.
  • Useful formulations also comprise concentrated solutions or solids containing peptide(s) of the invention which upon dilution with an appropriate solvent give a solution for parenteral administration as above.
  • a panel of overlapping synthetic peptides of MOG were screened for their ability to induce IFN ⁇ secretion from peripheral blood lymphocytes obtained from 20 DR2(15)+ MS patients and 14 DR2(15)+ healthy controls.
  • MOG peptide 63-87 The strongest response was observed with MOG peptide 63-87 which, together with the response to the known MBP epitope 82-104, was highly significant above the background levels of IFN ⁇ secreting cells (p ⁇ 0,01; figure 1 a b). MOG peptide 38-60, 76-100, 89-113, 162-178 and 168-182 also induced significantly more IFN ⁇ secreting cells than background levels (p ⁇ 0,05). When analysing responses in individual patients, most peptides were at the background level and responding peptides varied between patients. There was however a dominance also at the individual level for responses to MOG 63-87; which gave responses that were above two standard deviations from the mean group background in 7 of 20 MS patients (1 of 14 healthy controls).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)

Abstract

L'invention porte sur un peptide comportant une séquence immunodominante dérivant de la glycoprotéine de l'oligodendrocyte myélinique humain (MOG), sur des molécules d'acide nucléique codant pour ledit peptide, et sur l'emploi dudit peptide ou dudit acide nucléique à des fins de thérapie médicale et de criblage.
PCT/SE1998/001618 1997-09-11 1998-09-11 Peptides comportant une sequence immunodominante derivant de la glycoproteine de l'oligodendrocyte myelinique humain WO1999012966A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98944386A EP1012183A1 (fr) 1997-09-11 1998-09-11 Peptides comportant une sequence immunodominante derivant de la glycoproteine de l'oligodendrocyte myelinique humain
AU91938/98A AU9193898A (en) 1997-09-11 1998-09-11 Peptides comprising an immunodominant sequence derived from human myelin oligodendrocyte glycoprotein
CA002301684A CA2301684A1 (fr) 1997-09-11 1998-09-11 Peptides comportant une sequence immunodominante derivant de la glycoproteine de l'oligodendrocyte myelinique humain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703287-4 1997-09-11
SE9703287A SE9703287D0 (sv) 1997-09-11 1997-09-11 Peptides

Publications (1)

Publication Number Publication Date
WO1999012966A1 true WO1999012966A1 (fr) 1999-03-18

Family

ID=20408221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1998/001618 WO1999012966A1 (fr) 1997-09-11 1998-09-11 Peptides comportant une sequence immunodominante derivant de la glycoproteine de l'oligodendrocyte myelinique humain

Country Status (5)

Country Link
EP (1) EP1012183A1 (fr)
AU (1) AU9193898A (fr)
CA (1) CA2301684A1 (fr)
SE (1) SE9703287D0 (fr)
WO (1) WO1999012966A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060021A2 (fr) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation
US7560102B2 (en) 1998-05-19 2009-07-14 Yeda Research And Development Co., Ltd Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease
US9862751B2 (en) 2013-01-15 2018-01-09 Apitope Technology (Bristol) Limited Myelin oligodendrocyte glycoprotein peptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006727A2 (fr) * 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Utilisations de la glycoproteine de myeline d'oligodendrocytes et de portions peptidiques derivees de celle-ci dans des protocoles ayant trait a des maladies auto-immunes
WO1995007096A1 (fr) * 1993-09-06 1995-03-16 La Trobe University Traitement de maladies auto-immunes
WO1996012737A2 (fr) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions et traitement pour la sclerose en plaques
WO1997035879A1 (fr) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Peptides de la glycoproteine d'oligodendrocyte de myeline et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006727A2 (fr) * 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Utilisations de la glycoproteine de myeline d'oligodendrocytes et de portions peptidiques derivees de celle-ci dans des protocoles ayant trait a des maladies auto-immunes
WO1995007096A1 (fr) * 1993-09-06 1995-03-16 La Trobe University Traitement de maladies auto-immunes
WO1996012737A2 (fr) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions et traitement pour la sclerose en plaques
WO1997035879A1 (fr) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Peptides de la glycoproteine d'oligodendrocyte de myeline et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIALOG INFORMATION SERVICES, File 155, Medline, Dialog Accession No. 09353409, Medline Accession No. 98056819, KERLERO DE ROSBO N. et al., "Predominance of the Autoimmune Response to Myelin Oligodendrocyte Glycoprotein (MOG) in Multiple Sclerosis: Reactivity to the Extracellular Domain of MOG is Directed *
STN INTERNATIONAL, File CAPLUS, CAPLUS Accession No. 1995:223904, AMOR SANDRA et al., "Identification of Epitopes of Myelin Oligodendrocyte Glycoprotein for the Induction of Experimental Allergic Encephalomyelitis in SJL and Biozzi AB/H Mice"; & J. IMMUNOL., (1994), 153(10), 4349-56. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060021A2 (fr) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation
WO1999060021A3 (fr) * 1998-05-19 2000-06-15 Yeda Res & Dev Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation
US7560102B2 (en) 1998-05-19 2009-07-14 Yeda Research And Development Co., Ltd Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease
US9862751B2 (en) 2013-01-15 2018-01-09 Apitope Technology (Bristol) Limited Myelin oligodendrocyte glycoprotein peptides
US10377800B2 (en) 2013-01-15 2019-08-13 Apitope Technology (Bristol) Limited Myelin oligodendrocyte glycoprotein (MOG) peptide

Also Published As

Publication number Publication date
CA2301684A1 (fr) 1999-03-18
AU9193898A (en) 1999-03-29
EP1012183A1 (fr) 2000-06-28
SE9703287D0 (sv) 1997-09-11

Similar Documents

Publication Publication Date Title
AU2019202527B2 (en) Compositions and methods for modulating gamma-c-cytokine activity
JP3520086B2 (ja) 熱ショックタンパク質および腫瘍の治療
AU742970B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
US6942852B1 (en) N-terminal modifications of RANTES and methods of use
HU229489B1 (hu) Tolerogén peptidek
US8501189B2 (en) Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases
ES2326114T3 (es) Un peptido de hsp70 estimulador de la actividad de las celulas asesinas naturales (nk) y los usos del mismo.
EA009377B1 (ru) Еро-имитирующие миметические антитела человека с центральной шарнирной областью, композиции, способы и применения
HU220357B (hu) Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával
WO1994007520A9 (fr) Procede de traitement de la polyarthrite rhumatoide avec du collagene de type ii
KR19990022654A (ko) 보호 면역 반응을 증강시키는 방법
KR20080103560A (ko) 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신
CA2527039C (fr) Compositions d'analogues grf et leur utilisation
CA2203629A1 (fr) Compositions et traitement pour la sclerose en plaques
KR20030081490A (ko) 백신
WO1996012737A9 (fr) Compositions et traitement pour la sclerose en plaques
CA2187336A1 (fr) Formulations pharmaceutiques utilisees dans le traitement de la pollinose du cedre du japon
US7468353B2 (en) Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung diseases
US5958416A (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
CN115768468A (zh) 用于治疗covid-19的肽
EP1012183A1 (fr) Peptides comportant une sequence immunodominante derivant de la glycoproteine de l'oligodendrocyte myelinique humain
KR102499918B1 (ko) 근위축성 측삭 경화증 치료제
US8012487B2 (en) Synthetic peptides and DNA sequences for treatment of multiple sclerosis
US20070003580A1 (en) Anti-allergic pharmaceutical composition containing at least one allergen and at least one antihistamine compound
JP4422330B2 (ja) 新規な免疫異常性疾患予防・治療用剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09194618

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 91938/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2301684

Country of ref document: CA

Ref country code: CA

Ref document number: 2301684

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998944386

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998944386

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998944386

Country of ref document: EP